Market Overview

UPDATE: Jefferies Upgrades The Medicines Company to Buy on Attractive Risk/Reward

Share:
Related MDCO
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Leerink Swann Upgrades Medicines Company To Outperform

Jefferies raised its rating on The Medicines Company (NASDAQ: MDCO) from Hold to Buy and increased its price target from $24 to $34.

Jefferies commented, "We are upgrading MDCO to Buy from Hold with a new $34 PT on attractive reward/risk ahead of the cangrelor PHOENIX topline data ~early 2013. With cangrelor potentially under-appreciated given PHOENIX's complexity and previous PIII failures, we conducted a proprietary analysis to support 70% odds of success. Our DCF analysis supports a ~$10 upside on trial success, outweighing a $2-$3 downside driven by negative sentiment on failure."

The Medicines Company closed at $23.98 on Monday.

Latest Ratings for MDCO

DateFirmActionFromTo
Jan 2015CitigroupMaintainsNeutral
Jan 2015Leerink SwannUpgradesMarket PerformOutperform
Dec 2014JP MorganMaintainsOverweight

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters